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We previously demonstrated that Arg-Gly-Asp (RGD)-con-
taining ligand-mimetic inhibitors of integrins are unable to dis-
sociate pre-formed integrin-fibronectin complexes (IFCs).
These observations suggested that amino acid residues involved
in integrin-fibronectin binding become obscured in the ligand-
occupied state. Because the epitopes of some function-blocking
anti-integrinmonoclonal antibodies (mAbs) lie near the ligand-
binding pocket, it follows that the epitopes of these mAbs may
become shielded in the ligand-occupied state. Here, we tested
whether function-blocking mAbs directed against 51 can
interact with the integrin after it forms a complex with an RGD-
containing fragment of fibronectin.We showed that the anti-5
subunit mAbs JBS5, SNAKA52, 16, and P1D6 failed to disrupt
IFCs and hence appeared unable to bind to the ligand-occupied
state. In contrast, the allosteric anti-1 subunit mAbs 13, 4B4,
and AIIB2 could dissociate IFCs and therefore were able to
interact with the ligand-bound state. However, another class of
function-blocking anti-1 mAbs, exemplified by Lia1/2, could
not disrupt IFCs. This second class of mAbs was also distin-
guished from 13, 4B4, and AIIB2 by their ability to induce
homotypic cell aggregation. Although the epitope of Lia1/2 was
closely overlappingwith those of 13, 4B4, andAIIB2, it appeared
to lie closer to the ligand-binding pocket. A new model of the
51-fibronectin complex supports our hypothesis that the
epitopes ofmAbs that fail to bind to the ligand-occupied state lie
within, or very close to, the integrin-fibronectin interface.
Importantly, our findings imply that the efficacy of some thera-
peutic anti-integrin mAbs could be limited by epitope masking.
Integrins are a large family of - and -heterodimeric trans-
membrane receptors that mediate many cell-cell and cell-ma-
trix interactions (1). These interactions are indispensable for
normal development, cell survival, and organ and immune sys-
tem function. In many disorders, aberrant integrin function
plays a role in initiating, maintaining, or exacerbating the dis-
ease process. Several integrin family members are important
targets for therapy in autoimmunity, thrombosis, fibrosis, and
cancer, including 41, 47, IIb3, 51, V3, V6, and
V8 (2, 3). Currently, most efficacious integrin-based thera-
pies involve the use of humanized mAbs that block the ligand-
binding site of the integrin (4–6), and these drugs have com-
bined annual sales of over $2 billion (2). In contrast, some
mAb-based therapies have failed in clinical trials (7–9).
Ligand binding to integrins takes place in the so-called
“headpiece” domain (10, 11). This region includes the seven-
bladed -propeller domain of the  subunit and the I and
hybrid domains of the  subunit. Loops on the upper surface of
the -propeller and the top face of the I domain form the
ligand-binding pocket (12–17). The metal ion-dependent
adhesion site (MIDAS)3 on the top of theI domain is an essen-
tial site for binding to ligands that contain a carboxyl group
(such as the RGD peptide sequence) (11, 12, 17, 18). Some
integrin ligands contain a second site for integrin binding, such
as the Pro-His-Ser-Arg-Asn (PHSRN) synergy sequence in
fibronectin (19).
Integrins can exist in different conformational states, and
high affinity ligand binding requires an opening of the head-
piece (20–22). Headpiece opening involves shifts of the 1 and
7 helices in the I domain and an outward swing of the hybrid
domain away from the -propeller (11, 23–26). The epitopes of
function-blocking anti-integrin  subunit antibodies lie in
loops in blades 1–3 of the propeller, overlappingwith or close to
the loops involved in ligand recognition (27–31). The epitopes
of nearly all inhibitory anti- subunit mAbs lie within the I
domain (11, 21, 32–34). In the integrin 1 subunit, these
epitopes involve residues in the 2 helix of I (17, 18, 30), and
most of these mAbs appear to block integrin function by pre-
venting an inward movement of the adjacent 1 helix (17, 23).
* Thisworkwas supported in part by an award fromUniversity ofManchester
Intellectual Property Impact Scheme (to A. P. M. and T. A. J.) and Grants
092015 (to M. J. H.) and 105610/Z/14/Z (to M. J. H., A. P. M., and T. A. J.)
from theWellcomeTrust. The authorsdeclare that theyhavenoconflicts of
interest with the contents of this article.
Author’s Choice—Final version free via Creative Commons CC-BY license.
□S This article contains supplemental Video S1.
1 Present address: Dept. of Dermatology, Biochemistry and Molecular Medi-
cine, University of California at Davis School of Medicine, Sacramento, Cal-
ifornia 95817, and the Ph.D. Program for TranslationalMedicine, College of
Medical Science and Technology, Taipei Medical University, Taipei 11031,
Taiwan.
2 To whom correspondence should be addressed: Faculty of Life Sciences,
Michael Smith Bldg., University of Manchester, Oxford Rd., Manchester
M13 9PT, United Kingdom. Tel.: 44-161-275-5777; E-mail: martin.
humphries@manchester.ac.uk.
3 The abbreviations used are: MIDAS, metal ion-dependent adhesion site;
50K, 50-kDa fragment of fibronectin (3FN6–10); IFC, integrin-fibronectin
complex;mu IgG,mouse IgG; RB, runningbuffer; cRGD, cyclicGCRGDSPCG;
SPR, surface plasmon resonance.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 291, NO. 40, pp. 20993–21007, September 30, 2016
Author’s Choice © 2016 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
crossmark
SEPTEMBER 30, 2016•VOLUME 291•NUMBER 40 JOURNAL OF BIOLOGICAL CHEMISTRY 20993
Hence, many of these anti-1 mAbs have an allosteric mode of
action.
Recently, we showed that RGD-containing ligand-mimetic
inhibitors of integrins are unable to dissociate pre-formed IFCs
(35), a feature that could have contributed to the failure of com-
pounds such as cilengitide in cancer treatment (36, 37). Our
observations provided evidence that theRGD-binding pocket is
obscured in the macromolecular ligand-occupied state, i.e.
integrin residues involved in ligand recognition become buried
in the integrin-fibronectin interface. Because the residues that
form the epitopes of some function-blocking mAbs lie very
close to the ligand-binding pocket, it follows that the epitopes
of these mAbs may become obscured in the ligand-occupied
state. Hence, these mAbs could fail to bind to, or cause disrup-
tion of, IFCs.
Here, we have tested the ability of many different mAbs
directed against the  and  subunits of the fibronectin recep-
tor 51 to bind to and disrupt IFCs. We show that function-
blocking antibodies directed against the 5 subunit fail to dis-
sociate these complexes, suggesting that the epitopes of these
mAbs are masked. In contrast, most function-blocking anti-
bodies directed against the 1 subunit can disrupt IFCs, dem-
onstrating that the epitopes of these antibodies are still acces-
sible in the ligand-bound state. Additionally, we map the
epitope of the unusual anti-1 mAb Lia1/2, which, like the
anti-5 subunit mAbs, fails to dissociate integrin-ligand com-
plexes, and we provide evidence that its epitope partly overlaps
with the ligand-binding pocket. Our results suggest that
epitopes that are spatially close to residues involved in ligand
recognition become obscured in the IFC. An important corol-
lary of these data is that the effectiveness of some therapeutic
mAbs could be limited by their epitopes becoming masked in
ligand-occupied integrins.
Results
Function-blocking Anti-5mAbs Cannot Disrupt Pre-formed
51-Fibronectin Complexes—For surface plasmon resonance
(SPR) assays, we used the recombinant proteins 51-Fc (38),
the 50-kDa fragment of fibronectin (3FN6–10, “50K”), and a
control inactive mutant 50K-KGE in which the RGD sequence
is converted to Lys-Gly-Glu (Fig. 1). In this assay (35), 50K is
linked to the chip surface, and then recombinant 51-Fc is
flowed over the surface for 120 s, leading to the formation of
51–50K complexes. Subsequently, the complexes dissociate
slowly (see “Experimental Procedures” for further details). To
test the ability ofmAbs to affect the stability of IFCs,mAbswere
injected during the dissociation phase as described previously
(i.e. post-integrin injection) (35). Three possible outcomes
would be anticipated as follows: (i) if mAbs were unable to bind
to the complexes, there would be no effect on the dissociation
rate; (ii) if mAbs could bind to and cause disruption of IFCs,
there would be an observed increase in the dissociation rate; or
(iii) if mAbs could bind to IFCs without causing disruption,
there would be an increase in SPR signal due to mAb binding.
First, we tested whether the function-blocking anti-5 sub-
unit mAbs JBS5, SNAKA52, 16, and P1D6were able to alter the
dissociation rate of integrin-50K complexes. Key epitope resi-
dues of these mAbs lie in loop regions of the -propeller
domain (Table 1). The results (Fig. 2, cyan sensorgrams) showed
that none of these mAbs caused an increase in the dissociation
rate relative to the buffer-only channel (Fig. 2, red sensorgrams).
As a control, when these mAbs were added to the integrin
before binding to the fibronectin fragment (i.e. pre-integrin
injection), almost complete inhibition of complex formation
was observed (Fig. 2, blue sensorgrams). Hence, although these
mAbs could prevent complexes from forming, they could not
disrupt pre-formed IFCs, suggesting that these mAbs are
unable to bind to the complexes.
Function-blocking Anti-1 mAbs, with the Exception of Lia1/2,
Can Disrupt Pre-formed 51-Fibronectin Complexes—
Next, we tested whether the function-blocking anti-1 sub-
unit mAbs 13, 4B4, AIIB2, and Lia1/2 were able to increase
the dissociation rate of IFCs. Key epitope residues of the
mAbs 13, 4B4, and AIIB2 lie in the 2 helix region of the I
domain (Table 1), but the exact Lia1/2 epitope location is
unknown. The results (Fig. 3, cyan sensorgrams) showed that
13, 4B4, and AIIB2 caused amarked (4-fold) increase in the
dissociation rate, whereas Lia1/2 did not affect the dissocia-
tion rate (Fig. 3 legend). When these mAbs were pre-mixed
with the integrin before binding to the fibronectin fragment
(Fig. 3, blue sensorgrams), 13, 4B4, and AIIB2 showed a par-
tial (70%) inhibition of complex formation, whereas Lia1/2
caused a near-complete inhibition, comparable with that
seen for the function-blocking anti-5 mAbs. Hence, 13,
4B4, and AIIB2 can bind to and disrupt IFCs; members of
this group of mAbs appear to have an allosteric mode of
action (35). In contrast, Lia1/2 cannot bind to or disrupt
IFCs and seem to have properties similar to the anti-5
mAbs.
Non-function-blockingmAbs Can Bind to but DoNot Disrupt
Pre-formed 51-Fibronectin Complexes—Finally, we tested
the effect of the non-function-blocking anti-5 subunit (Fig. 4,
FIGURE 1. SDS-PAGE of the recombinant integrin and fibronectin frag-
ments used in these experiments. Samples were run on a 4–12%gel under
reducing conditions. Lane 1,51-Fc; lane 2, biotinylated 50K; lane 3, biotiny-
lated 50K-KGE. Positions of molecular mass markers (kDa) are shown. A band
in the 51-Fc sample running just below the 50-kDa marker probably cor-
responds to a partial cleavage product of the 5 light chain-Fc subunit
(5-Fc).
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A–C) and anti-1 subunit (Fig. 4, D–F) mAbs on 51-fi-
bronectin complexes. The epitopes of these mAbs lie outside
the ligand-binding region (Table 1). All of the mAbs caused an
increase in SPR signal when added during the dissociation
phase, indicative of mAb binding to the complexes (Fig. 4, cyan
sensograms) without causing disruption. With the exception of
JB1A, none of these antibodies caused an increase in the disso-
ciation rate of the complexes subsequent tomAbbinding (Fig. 4
TABLE 1
The properties and epitope location of anti-5 and anti-1mAbs used in this study
mAb Property Epitope location
JBS5 Function blocking 5 -propeller domain Ser-85 (27)1
SNAKA52 Function blocking 5 -propeller domain Ser-85 (27)1
P1D6 Function blocking 5 -propeller domain Leu212 (27)
16 Function blocking 5 -propeller domain Glu-126/Leu-128/Trp-157 (27, 68, 69)a
VC5 Neutral 5 -propeller domain (70)
11 Neutral 5 Calf-2 domain His-770/Arg-772 (71)
SNAKA51 Activating (weak) 5 Calf-1/Calf-2 domains (39, 68)
13 Function blocking 1 I domain Asn-207–Lys-218 (32)
4B4 Function blocking 1 I domain Ly-s218 (32)
AIIB2 Function blocking 1 I domain Val-211 (32)
Lia1/2 Function blocking 1 unknown
3S3 Function blocking 1 unknown
6S6 Function blocking 1 unknown
HUTS-4 Activating (weak) 1 hybrid domain Ser-370/Glu-371/Lys-417 (24)
JB1A Neutral 1 hybrid domain Asn-82–Lys-87 (72)
8E3 Activating (weak) 1 PSI domain Glu-4 (40)
TS2/16 Activating (strong) 1 I domain Asn-207–Lys-218 (32)
K20 Neutral 1 I-EGF domains (32)
a In the original paper (27), Ser-85 was incorrectly designated as Ser-75, and Glu-126 and Leu-128 were incorrectly designated as Glu-116 and Leu-118.
FIGURE 2. Effect of function-blocking anti-5mAbs on integrin-fibronectin complexes. A–D, binding of 51-Fc to 50K fibronectin fragment took place
for 120 s in three parallel channels in RB. In the blue sensorgrams, integrin was pre-mixed with 100 nM of the indicated anti-5 mAb. 60 s after the start of the
dissociation phase, at the time indicated by the downward-pointing arrow (207 s), either RB alone (red and blue sensorgrams) or RB with 100 nM mAb (cyan
sensorgrams) was injected for 120 s.A, dissociation rate in buffer alonewas 9.73 104 s1 and in thepresence of JBS5was 8.98 104 s1. B, dissociation rate
in buffer alone was 9.75 104 s1 and in the presence of mAb was 16 9.87 104 s1. C, dissociation rate in buffer alone was 9.70 104 s1 and in the
presence of P1D6was 9.24 104 s1.D, dissociation rate in buffer alone was 7.93 104 s1 and in the presence of SNAKA52 6.44 104 s1. Dissociation
rates were measured between 208 and 330 s. Similar results were obtained in three separate experiments.
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legend). Furthermore, all of the other non-function-blocking
mAbs were able to slightly decrease the dissociation rate, even
though the measured dissociation rates of mAb-51-fi-
bronectin complexes will also include a component from the
dissociation of mAb binding to the integrin. Some of these
mAbs (SNAKA51, 8E3, and HUTS-4) have previously been
shown to be weakly activating and hence may be capable of
directly stabilizing IFCs (24, 39, 40). All the mAbs showed no
inhibition of complex formation when pre-mixed with the
integrin (data not shown). In summary, although all these non-
function-blocking mAbs bound to IFCs, no disruption of the
complexes was observed.
Lia1/2 Binding to 51 Is Strongly Perturbed by Ligand
Recognition—The unusual properties of Lia1/2 prompted us to
explore further itsmechanism of action.We previously showed
that the binding of some function-blocking mAbs to 1 is
inhibited by RGD-containing peptides and fibronectin frag-
ments (15, 41).We therefore tested the effect of 50K and cRGD
on the binding of Lia1/2 to 51, and we simultaneously com-
pared the effect of these reagents on the binding ofmAbs 13 and
4B4. The results (Fig. 5, A and B) showed that Lia1/2 binding
was more strongly inhibited by 50K and cRGD than was the
binding of mAbs 13 and 4B4. In control experiments (data not
shown), the 50K-KGE mutant protein had no effect on mAb
binding. We next tested whether the cRGD peptide acted as an
allosteric or a competitive inhibitor of Lia1/2 binding (Fig. 5C).
In this experiment, the effect of cRGD on binding of Lia1/2 to
51 was tested over a 10-fold range of mAb concentrations.
The results (Fig. 5 legend) showed that the concentration of
cRGD peptide for half-maximal inhibition increased at the
higher antibody concentration. If ligand behaved as a purely
allosteric inhibitor of mAb binding, the concentration of pep-
tide for half-maximal inhibition should be unchanged, and the
maximal extent of inhibition should decrease with increased
antibody concentration (as we previously observed for mAb13
binding (41)). In contrast, if ligand behaved as a direct com-
petitive inhibitor of mAb binding, the concentration of
ligand for half-maximal inhibition of antibody binding
should increase in proportion to the antibody concentration,
and the maximal extent of inhibition should be unchanged.
However, for Lia1/2 binding, we observed that the concen-
tration of cRGD peptide for half-maximal inhibition
increased 2–3-fold for a 10-fold increase in antibody con-
centration, and the maximal extent of inhibition decreased.
FIGURE 3. Effect of function-blocking anti-1mAbs on integrin-fibronectin complexes. A–D, binding of 51-Fc to 50K fibronectin fragment took place
for 120 s in three parallel channels in RB. In the blue sensorgrams, integrin was pre-mixed with 100 nM of the indicated anti-1 mAb. 60 s after the start of the
dissociation phase, at the time indicated by the downward-pointing arrow (207 s), either RB alone (red and blue sensorgrams) or RB with 100 nM mAb (cyan
sensorgrams) was injected for 120 s. Dissociation rates weremeasured during the buffer or mAb injection step (208–228 s). A, dissociation rate in buffer alone
was 1.11 103 s1 and in thepresence ofmAb13was 4.98 103 s1. B, dissociation rate in buffer alonewas 1.01 103 s1 and in thepresence of 4B4was
4.04 103 s1. C, dissociation rate in buffer alone was 1.37 103 s1 and in the presence of AIIB2 was 4.31 103 s1. D, dissociation rate in buffer alone
was 0.91 103 s1 and in the presence of Lia1/2 was 1.05 103 s1. Similar results were obtained in three separate experiments.
LigandOccupancy CausesMasking of Epitopes in51
20996 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 40•SEPTEMBER 30, 2016
These data indicate that the inhibition by cRGD is partly
competitive and partly allosteric in nature.
Epitope Mapping of Lia1/2—The epitope of Lia1/2 has not
been accurately mapped. We initially used mouse/human and
chicken/human1 chimeras to localize the epitope to a specific
region of 1. The results (Table 2) showed that the Lia1/2
epitope was included in a region containing amino acids 190–
304, which is part of the I domain. The same region has pre-
viously been shown to include the epitopes of mAbs 13, 4B4,
AIIB2, and TS2/16 (32). Because there are only five amino acid
changes in this region from mouse to human 1, point muta-
tions in each of these five residues (Asn-207, Lys-208, Val-211,
Lys-218, andMet-287) weremade, essentially as described pre-
viously (32). The results (Tables 3 and 4) showed that no single
point mutation abrogated Lia1/2 binding, although this is also
the case with several other mAbs that bind to this region,
FIGURE 4. Effect of non-function-blocking anti-5 and anti-1 mAbs on integrin-fibronectin complexes. A–F, binding of 51-Fc to 50K fibronectin
fragment took place for 120 s in three parallel channels in RB. In the blue sensorgrams, integrin was pre-mixed with 100 nM of the indicated anti-5mAb (A–C)
or anti-1mAb (D–F). 60 s after the start of the dissociation phase, at the time indicated by the downward-pointing arrow (207 s), either RB alone (red and blue
sensorgrams) or RBwith 100 nMmAb (cyan sensorgrams) was injected for 120 s. Dissociation rates weremeasured after the end of the buffer ormAb inject step
(330–390 s) for51-fibronectin complexes (red sensorgrams) ormAb-51-fibronectin complexes (cyan sensorgrams).A, dissociation rateswere 8.75 104
and 3.59 104 s1, respectively. B, dissociation rates were 11.3 104 and 3.26 104 s1, respectively. C, dissociation rates were 8.47 104 and 4.47
104 s1, respectively. D, dissociation rates were 7.55 104 and 4.33 104 s1, respectively. E, dissociation rates were 8.10 104 and 3.28 104 s1,
respectively. F, dissociation rates were 6.73 104 and 12.9 104 s1, respectively. Similar results were obtained in three separate experiments.
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including 13 and TS2/16 (32). Four of the mutated residues,
Asn-207, Lys-208, Val-211, and Lys-218, lie within the 2 helix
region of theI domain (17, 18). However, Lia1/2 did react with
the previously described “CHmutant” (32), which contains the
sequence of human 1 residues 207–218 in the context of
chicken 1 (data not shown), and hence its epitope directly
overlaps with that of other function-perturbing anti-1 mAbs.
Anti-1 mAbs That Induce Homotypic Aggregation Fail to
Disrupt 51-Fibronectin Complexes—Treatment of mononu-
clear cells with some function-blocking anti-1 mAbs can
cause homotypic cell aggregation (42–47), a poorly understood
phenomenon that requires integrin-mediated intracellular sig-
naling (42, 48). The epitopes ofmany function-blocking anti-1
mAbs have previously been sub-divided into two sub-classes,
A1 and A2; although the epitopes of these two classes overlap,
members of the A1 class can be distinguished from those of the
A2 class by their ability to induce homotypic aggregation (44).
The A1 class is known to include Lia1/2 (44). We tested the
ability of the function-blocking anti-1mAbs used in this study
to induce homotypic aggregation of Jurkat T-lymphoblastic
cells, using the activating mAb TS2/16 as a negative control
(Fig. 6,A–F). Our results showed thatmAb 13 did not cause cell
aggregation, and 4B4 and AIIB2 caused only the appearance of
some small aggregates of cells. In contrast, Lia1/2 caused the
appearance of very large clusters of cells, and so was the only
mAb of this group able to strongly trigger homotypic aggrega-
tion. Hence, mAbs 13, 4B4, and AIIB2 are members of the A2
class.
We next tested whether other anti-1 mAbs that have been
reported to induce homotypic aggregation had properties sim-
ilar to those of Lia1/2. We obtained the mAbs 3S3 and 6S6 (47)
and confirmed that these mAbs were able to strongly induce
cell aggregation (Fig. 6,G andH). It has been previously shown
that cell aggregation induced by some anti-1 mAbs can be
specifically inhibited by ceramide analogs (42). Aggregation
caused by Lia1/2, 3S3, and 6S6 was blocked to a similar extent
by the cell-permeable compound N-hexanoyl-D-sphingosine
(C6-ceramide) (Fig. 7), indicating that all three mAbs trigger
cell aggregation via a common mechanism involving intracel-
lular signaling.
We then examined the effect of 3S3 and 6S6 on the formation
and dissociation of 51-fibronectin complexes (Fig. 8, A and
B). The twomAbs inhibited the formation of IFCs (Fig. 8,A and
B, blue sensorgrams), although they were less potent inhibitors
of complex formation than Lia1/2. Significantly, like Lia1/2,
both 3S3 and 6S6 were unable to disrupt pre-formed IFCs (Fig.
8, A and B, cyan sensorgrams). A very small increase in signal
was consistently observed during the time window that these
mAbs were injected over the complexes, suggesting that they
could bind very weakly to the complexes, although this binding
had no effect on the overall dissociation rate.
FIGURE 5. Effect of 50K fibronectin fragment and cyclic RGD peptide on
Lia1/2binding to51.A andB, ability of 50K (A) or cyclic RGDpeptide (B) to
inhibit binding of Lia1/2 (closed circles) to 51 was tested in a solid-phase
assay, in parallel with mAbs 13 (closed triangles) and 4B4 (open circles). C, test
of competitive inhibition by cRGD peptide on Lia1/2 binding to 51. The
effect of cRGD was tested at 10-fold different concentrations of Lia1/2 (0.05
and 0.5 g/ml; open and closed circles, respectively). In this experiment, the
concentration of cRGD for half-maximal inhibition of Lia1/2 bindingwas esti-
mated by non-linear regression analysis to be 0.231 and 0.503g/ml for 0.05
and 0.5 g/ml of Lia1/2, respectively. In n  4 experiments, the concentra-
tions of cRGD for half-maximal inhibition were 0.211  0.059 and 0.538 
0.130 g/ml for 0.05 and 0.5 g/ml of Lia1/2, respectively (mean S.D., p
0.005, Student’s t test).
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The epitopes of 3S3 and 6S6 have not been localized to a
specific region of 1. To test whether the epitopes of these
mAbs map to the same region of 1 as Lia1/2, we used a com-
petitive ELISA (Fig. 8C). In this assay, we used biotinylated
Lia1/2 and competed its binding to 51 using a large excess of
unlabeled mAbs. The binding of biotinylated Lia1/2 was abro-
gated by themAbs 13, 4B4, andAIIB2, as well as TS2/16 (32), in
agreement with our epitope mapping data above. Significantly,
both 3S3 and 6S6 also strongly inhibited Lia1/2 binding,
whereas the control mAbs 8E3 and K20, whose epitopes lie
outside of the I domain (Table 1), had little effect on Lia1/2
binding. Therefore, the epitopes of 3S3 and 6S6 appear to be
closely overlapping with the epitope of Lia1/2. Hence, like
Lia1/2, 3S3 and 6S6 are members of the A1 class.
New Model of the 51-Fibronectin Complex Supports the
Epitope-masking Hypothesis—The failure of some function-
blocking mAbs to disrupt IFCs suggests that these mAbs are
unable to bind to IFCs because their epitopes become masked
in the ligand-bound state of 51. To test this possibility fur-
ther, a model of the 51-fibronectin complex (Fig. 9 and
supplemental Video S1) was constructed based on the crystal
structure of 3FN10 bound toV3 (49) and theNMR structure
of murine 3FN9,10 (50). 3FN9 contains the synergy region,
whereas 3FN10 contains the RGD sequence. The orientation of
3FN9,10 was guided by docking the fragment onto the 51
crystal structure (18), with 3FN10 in the same orientation as in
the V3 crystal structure (49). Only minimal adjustments in
the position of 3FN9 were required to prevent steric clashes
between 3FN9 and -propeller residues (see “Experimental
Procedures”). To estimate the antibody-accessible surface, we
rolled a 20-Å sphere (the approximate size of a Fab fragment)
over the structure (51). The results (Fig. 10) indicated that 5
residues Leu-212 (P1D6 epitope), Glu-126/Leu-128/Trp-157
(mAb 16 epitope), and Ser-85 (JBS5 and SNAKA52 epitopes)
would not be accessible in the ligand-occupied state. In con-
trast, 1 residues Val-211 and Lys-218, forming part of the
AIIB2 and 4B4 epitopes, respectively, would be accessible. The
epitopes of non-function-blocking mAbs (data not shown)
were also fully available in this model. The exact location of the
Lia1/2 epitope is not known, but it appears to lie closer to
3FN10 than the epitopes of AIIB2 and 4B4.
Only Allosteric Anti-1 mAbs Can Cause Complete Detach-
ment of Fibrosarcoma Cells Pre-spread on Fibronectin—Finally,
to examine the relevance of our findings to cell-surface 51,
we tested the ability of function-blocking anti-5 and anti-1
mAbs to cause rounding up ofHT-1080 cells pre-spread on 50K
(i.e.with cell-surface 51 in complex with ligand). The results
(Fig. 11A) showed that the allosteric anti-1 mAbs 13, AIIB2,
and 4B4 could cause complete rounding up of cells (no spread
cells remaining). In contrast, the function-blocking anti-5
mAbs JBS5, 16, P1D6, and SNAKA52, and the anti-1 mAb
Lia1/2 caused only a slight reduction (typically  25%) in the
degree of cell spreading. In control experiments, run in parallel,
Lia1/2 and the function-blocking anti-5 mAbs were potent
inhibitors of cell spreading when added to the cells before plat-
ing on 50K (Fig. 11B).
Discussion
Themajor findings of this report are as follows. (i) Function-
blocking anti-5 mAbs cannot cause dissociation of IFCs, and
the epitopes of these mAbs appear to be masked in the ligand-
occupied state. (ii) Allosteric function-blocking anti-1 mAbs
(A2 class) can cause disruption of IFCs, and the epitopes of
these mAbs do not appear to be masked by ligand. (iii) Mem-
bers of a second group of function-blocking anti-1 mAbs (A1
class), which includes Lia1/2, fail to disrupt IFCs, suggesting
that their epitopes are obscured in the IFC. (iv) In accord with
our in vitro data, only allostericmAbs could disrupt cell-surface
51-fibronectin interactions.
Apreceding study defined theA1 andA2 classes of inhibitory
anti-1 mAbs (44). From our results, it appears that the mem-
bers of the A1 class are distinguished from the A2 class not only
by their ability to induce cell aggregation but also by their
inability to dissociate IFCs. Lia1/2 appears to have a similar
TABLE 2
The reactivity of Lia1/2 to wild-type and different chimeric 1 chains by flow cytometry
The numbers in the table representmean fluorescence intensity values in the typical experiments using CHOcells stably expressingwild-type or chimeric1. / represents
positive reactivity of the transfected cells to the mAbs; / represents no reactivity. Mouse IgG was used as a control.
Antibody CHO h587/m h425/m h354/m h304/c h189/c
Mouse IgG 3.52 4.48 4.05 4.92 6.24 5.49
Lia1/2 4.33/ 75.01/ 40.26/ 163.51/ 71.45/ 5.22/
TABLE 3
Reactivity of Lia1/2 to wild-type andmutant human 1 chains by flow cytometry
Human 1 chains with human-to-mouse mutations were transiently expressed on CHO cells, and the reactivity of the cells to mAbs was examined by flow cytometry;
numbers represent mean fluorescence intensity values. Clonal CHO cells stably expressing human wild-type 1 were used as positive control. / represents positive
reactivity to the mAbs.
Antibody CHO N207D K208R V211F K218Q Human 1
Mouse IgG 3.93 2.73 4.47 2.99 5.08 3.92
Lia1/2 4.61/ 183.79/ 126.30/ 108.92/ 54.86/ 260.94/
TABLE 4
Reactivity of Lia1/2 towild-type andmutant human1 chains by flow
cytometry
CHO-K1 cells transiently expressing wild-type or M287V mutant 1-GFP were
examined by flow cytometry for reactivity with TS2/16 or Lia1/2; numbers repre-
sentMFI values. / represents positive reactivity to themAbs.Mouse IgGwas used
as a control.
Antibody M287V Human 1
Mouse IgG 247 270
TS2/16 11,512/ 11,780/
Lia1/2 14,856/ 14,111/
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mode of inhibition to the function-blocking anti-5mAbs, act-
ing in a predominantly steric, rather than allosteric, manner.
The partially competitive effect of RGDpeptide on Lia1/2 bind-
ing supports the notion that the Lia1/2 epitopemay lie closer to
the binding site of 3FN10 than the epitopes of other function-
blocking anti-1 mAbs, leading to masking of its epitope in the
IFC.
The mechanism of anti-1 mAb-induced cell-cell aggrega-
tion remains unclear, although previous studies (43–46) have
demonstrated that this aggregation requires 41 integrins.
There is evidence that these mAbs induce a functional associa-
tion between 1 and CD98 and CD147 and that this complex
causes intracellular signals that result in the induction of cell-
cell adhesiveness (48). Similar to a previous report with the
anti-1 mAbMEM 101A (42), C6-ceramide blocked the aggre-
gation of Jurkat cells promoted by Lia1/2, 3S3, and 6S6, suggest-
ing the involvement of similar intracellular signaling pathways
by all these mAbs. Recent studies with tumor cells suggest that
these pathways involve members of the PKC family (52). Eluci-
dation of the precise mechanisms by which A1 class mAbs
cause different signals to those of the A2 class will require fur-
ther investigation. However, the distinct (but overlapping)
epitope location of these two classes provides a novel insight
into this conundrum. Aggregation of T-cells is important in
vivo for T-cellmaturation (53); it is therefore intriguing to spec-
ulate that A1 class mAbs mimic the function of one or more
natural proteins that can bind to this region of the 1 subunit.
An important inference of our studies is that function-block-
ing anti-integrin subunit mAbs are not all equivalent (as has
often been assumed). It is important for researchers to test sev-
eral different mAbs to find the one that functions best in their
specific application. Our findings demonstrate that, particu-
larly in assays where cells or purified integrins are pre-bound to
the ligand, the choice of mAb is critical. Only allosteric mAbs
have the capacity to disrupt pre-existing interactions.
It could be argued that the inability of some function-block-
ingmAbs to perturb pre-formed cell-surface integrin-fibronec-
tin interactions (Fig. 11A) was due to poor accessibility of these
mAbs to cell adhesion sites. We consider this explanation to be
unlikely because the allostericmAbs cause complete disruption
of cell spreading, and hence these mAbs must be able to access
the adhesion sites. Instead, the failure of certainmAbs tomark-
edly disrupt cell spreading appears to correlate with our in vitro
data showing that the epitopes of these mAbs are occluded in
FIGURE 6. Effect of anti-1mAbs on homotypic aggregation of Jurkat cells. A–H, cells (5 105/ml) were incubated for 2 h at 37 °C in the presence of the
indicatedmAbs and photographed using a phase-contrastmicroscope. Scale bars, 50m. Inset shows histogram ofmean aggregate size, averaged over three
fields of view (mean S.D.) for no mAb (None), TS2/16 (TS2), 13, 4B4, AIIB2, Lia1/2, 3S3, and 6S6. The experiment shown is representative of three separate
experiments.
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the IFC. A slow turnover of cell adhesion sites (which would
re-expose integrin epitopes) may account for the small amount
of inhibition of cell spreading by the non-allosteric inhibitory
mAbs seen over the 1-h time period of the assay.
In our new model of the IFC (Figs. 9 and 10), the synergy
region of 3FN9 lies very close to the residues Trp-208 and Ile-
210 in the 5 subunit -propeller domain, as proposed previ-
ously (15, 54). Significantly, P1D6 (whose epitope includes Leu-
212) only blocks interaction of51with fibronectin fragments
FIGURE 7. Effect of C6-ceramide on homotypic cell aggregation stimu-
lated by anti-1 mAbs. Jurkat cells (8  105/ml) were incubated for 2 h at
37 °C in thepresenceof the indicatedmAbs, in thepresenceofDMSO (solvent
control) or 10 M C6-ceramide, and photographed using a phase-contrast
microscope. C6-ceramide did not cause any reduction in cell viability over the
time course of the experiment (	97% of cells were viable both before and
after the experiment, as determined by propidium iodide staining, data not
shown). Scale bars, 50 m. TS2/16 is used as a negative control mAb in this
assay. Inset shows histogram of mean aggregate size, averaged over three
fields of view (mean S.D.). The experiment shown is representative of three
separate experiments.
FIGURE8.CharacterizationofmAbs3S3and6S6.A andB, SPR test of compet-
itiveorallosteric inhibitionby3S3and6S6.Bindingof51-Fc to50K fibronectin
fragment took place for 120 s in three parallel channels in RB. In the blue sensor-
grams, integrinwaspre-mixedwith200nM3S3 (A) or6S6 (B). 60 safter thestartof
the dissociation phase, at the time indicated by the downward-pointing arrow
(207 s), eitherRBalone (redandblue sensorgrams) or RBwith200nMmAb (cyan
sensorgrams) was injected for 120 s. C, competitive ELISA experiment to test
whether epitopes of 3S3 and 6S6 overlapwith that of Lia1/2. Binding of biotiny-
lated Lia1/2 to 51-Fc was competed by a large excess of unlabeledmAbs 13,
4B4, AIIB2, 4B4, TS2/16 (TS2), 3S3, 6S6, 8E3, or K20. Con, control. Similar results
were obtained in three separate experiments.
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that contain the synergy region, suggesting that it binds close to
a site on the5 subunit that interacts with the synergy region of
3FN9 (15). Nevertheless, there has been some dispute as to
whether or not the synergy region binds directly to the 5 sub-
unit. For example, a lack of interaction of 3FN9 with the 5
subunit -propeller domain was observed by negative staining
and electron microscopy (55). In contrast, mutagenesis of 5
residues close to Leu-212, includingTrp-208 and Ile-210, or the
equivalent Trp-204 and Ile-206 in zebrafish 5, specifically
blocks interaction of51with fibronectin fragments that con-
tain the synergy region (15, 54). In addition, theW204Nmuta-
tion leads to loss of 51 function in zebrafish development
(56). Because the interaction of 3FN9 with the 5 subunit is
weak, it could easily be disrupted by the high ionic strength
conditions used for negative staining. Our new data support a
direct interaction of 3FN9 with the Leu-212 region of the
-propeller because they provide evidence that the epitope of
P1D6 is masked in the ligand-occupied state, and so, like the
other 5 subunit mAbs, the epitope of P1D6 lies close to an
interface between 3FN9 and the -propeller. Binding of P1D6
to the5 subunit is strongly inhibited by 3FN9-containing frag-
ments (15), consistent with our model. An alternative model of
the complex between 3FN9,10 and 51 has been previously
proposed by Nagae et al. (17), in which 3FN9,10 lies in a groove
between the  and  subunits. Our model uses the same
3FN9,10 structure as the Nagae model but incorporates new
information on the position of 3FN10 (49) to direct the orien-
tation of 3FN9. In the Nagae model, although the epitope resi-
dues of mAbs JBS5, SNAKA52, and 16 would still be predicted
to be obscured by fibronectin binding, the P1D6 epitope residue
Leu-212 would be minimally masked. The principle of epitope
occlusion used here could also be utilized in other receptor-
ligand systems to help define the boundary of the receptor-
ligand interface.
A recent study of the location of epitopes in integrin  sub-
units identified the 4-1 loop of -propeller blade 2 (which in 5
contains the JBS5 and SNAKA52 epitopes) and the 3-4 loop of
-propeller blade 3 (P1D6 epitope in 5) as the site of	80% of
function-blocking mAb epitopes (29). Hence, the results of our
study are likely to be applicable to a large proportion of other 
subunitmAbs, i.e. epitopemasking by ligand occupancy is likely
to be a common feature in other integrins.
Accordingly, it is important to note that the epitopes of some
therapeutic anti-integrinmAbs, such as the anti-4mAbTysa-
bri/natalizumab and the anti-V mAb 17E6, may be partly
obscured in the ligand-occupied state (30, 31). Consequently,
complete blockade of integrin function by these biologicals
would be dependent on turnover of integrin-ligand complexes
to re-expose integrin epitopes, and this turnover can be very
slow (35, 57–60). For example, we previously observed that
51-fibronectin complexes gradually transition to a very
long-lived state, koff 105 s1, i.e. t1⁄2 19 h (35). Our study
suggests that epitopemasking could reduce the effectiveness of
drugs like Tysabri, and in the future it will be important to test
whether their efficacy could be enhanced by co-administration
of an allosteric inhibitor. Epitope masking could also have con-
tributed to the lack of efficacy of some blocking anti-integrin
mAbs in clinical trials (7–9).
In summary, our findings re-emphasize the importance of
allosteric inhibition for effective blockade of integrin function
(35). Allosteric anti-1 mAbs such as AIIB2 are already show-
ing therapeutic potential for radiosensitization of tumors and
prevention of metastasis (61–63). Finally, ligand-induced
epitope masking may occur in other receptor-ligand systems,
and in the future it will be important to address whether this
phenomenon limits the efficacy of non-integrin function-
blocking therapeutic mAbs.
Experimental Procedures
Materials—The production of recombinant integrin 51-Fc
has been previously described (38). In brief, 51-Fc was pro-
duced in NS0 cells and purified from culture medium using
protein A-Sepharose. mAb TS2/16 was a gift from F. Sa´nchez-
Madrid (Hospital de la Princesa, Madrid, Spain); mAbs JB1A,
3S3, and6S6were gifts from J.A.Wilkins (University ofManitoba,
Winnipeg,Manitoba,Canada); andmAbs 11, 13, and 16were gifts
fromK.M. Yamada (National Institutes of Health, Bethesda). 4B4
was fromBeckmanCoulter (UK). SNAKA51, 8E3, and SNAKA52
have been previously described (39–40, 64). P1D6, AIIB2, and
HUTS-4 were from Merck Millipore (UK). VC5 and JBS5 were
purchased from Pharmingen and Serotec (UK), respectively. K20
was a gift from P. T. Caswell (University of Manchester, Man-
FIGURE9.Modelofheadpiece regionof51boundto3FN9,10, showing
epitopesof function-blockingmAbs. In themodel, the5 subunit is shown
as a blue ribbon,1 subunit as a green ribbon, and 3FN9,10 as a semi-transpar-
ent light gray surface. In the 5 subunit, residue Leu-212 (P1D6 epitope) is
shown in yellow; residuesGlu-126, Leu-128, andTrp-157 (mAb16epitope) are
shown in orange, and residue Ser-85 (JBS5 and SNAKA52 epitopes) is shown
in red. In the 1 subunit, residues Val-211 (AIIB2 epitope) and Lys-218 (4B4
epitope) are shown in brown and cyan, respectively. The MIDAS Mg2 ion is
depictedasadarkblue sphere; Ca2 ionsat theSyMBS (synergisticmetal-binding
site) andADMIDAS (adjacent toMIDAS) sites (flanking theMIDAS site) are shown
as dark red spheres. The2 helix in theI domain is shown inmagenta. Residues
that contribute to the epitopes ofmAbs 13, 4B4, and AIIB2 lie in the2 helix (5).
Inset shows an x axis-rotated view,with residues labeled in themainmodel indi-
cated by arrowheads for reference (5 subunit residues, black arrowheads; 1
subunit residues,white arrowheads). Scale bars, 20Å.
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chester, UK), and Lia1/2 was from Biorbyt (UK). For competitive
ELISAs, Lia1/2 was biotinylated using sulfo-N-hydroxysuccinim-
ide-LC-biotin (64). Further details of all the mAbs used in this
study are shown in Table 1.
The 50-kDa cell-binding domain fragment of human
fibronectin (3FN6–10, 50K) and the inactive mutant (50K-
KGE) were produced in Escherichia coli and purified as before
(15, 16). 50K and 50K-KGE were biotinylated and purified by
gel filtration as described previously (35). Both proteins contain
a single site for biotinylation in 3FN7. Avidin (from egg white)
was obtained from Life Technologies, Inc. Peptide GCRGD-
SPCG (cRGD) was purchased from Peptide 2.0, Inc., and cycl-
ized by oxidation as described previously (16). N-Hexanoyl-D-
sphingosine (C6-ceramide), ExtrAvidin peroxidase, bovine
serum albumin (BSA), and mouse IgG were purchased from
Sigma.
FIGURE 10. Putative accessibility of epitopes of function-blockingmAbs in amodel of the headpiece of51 bound to 3FN9,10. A–E, molecularmodel
is the same as that shown in Fig. 9. In respective panels, residue Leu-212 (P1D6 epitope) is shown in yellow; residues Glu-126, Leu-128, and Trp-157 (mAb 16
epitope) are shown in orange; residue Ser-85 (JBS5 and SNAKA52 epitopes) is shown in redwithin the 5 subunit (blue ribbon); residue Val-211 (AIIB2 epitope)
is shown in brown, and residue Lys-218 (4B4 epitope) is shown in cyanwithin the1 subunit (green ribbon). The2 helix in theI domain is shown inmagenta.
3FN9,10 is shown as a semi-transparent light gray surface, and the surface of accessible 3FN9,10 residues within 20 Å of indicated mAb epitope residues is
rendered in semi-transparent pink. Residue Arg-1468 (from the Pro-Pro-Ser-Arg-Asn synergy sequence of murine fibronectin) is shown in dark pink and
indicated by the pink text in A. Anti-5 mAbs would be sterically hindered from binding to indicated epitope residues by fibronectin, whereas anti-1 mAbs
would not. Scale bars, 20 Å.
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SPR—Experiments were performed using the ProteOn
XPR36 instrument (Bio-Rad). Running buffer (RB) was 150mM
NaCl, 10 mMHEPES, 0.05% (w/v) Tween 20, pH 7.4, with 1 mM
MnCl2. Immobilization of avidin was performed on aGLC chip
(Bio-Rad) in the vertical orientation. Two channels were acti-
vated with 150 l of a 1:1 mixture of 20 mM N-ethyl-N
-(3-
dimethylaminopropyl)carbodiimide and 11 mM sulfo-N-hy-
droxysuccinimide in water at a flow rate of 30 l/min. Avidin
was diluted in RB to a final concentration of 1.2 M, and 150 l
was injected, followed by an injection of 150 l of 1 M ethanol-
amine-HCl, pH 8.5, at a flow rate of 30 l/min. The immobili-
zation level of avidin was3200 resonance units. Next, 150 l
of biotinylated 50K-KGE in one vertical channel and biotiny-
lated 50K in the second (20–200 nM) in RB were injected to
allow their capture by the immobilized avidin. Injection of 50K
and 50K-KGE was repeated as necessary to give equivalent
immobilization levels of the two proteins. The 50K-KGE chan-
nel was used as a reference. Final immobilization levels were in
the range 100–300 resonance units. All experiments were per-
formed at 25 °C.
To test the effect ofmAbs on the dissociation rate of integrin-
50K complexes, 100 l of 51-Fc in RB was injected in three
parallel horizontal channels at 50 l/min, and binding to 50K
was allowed to occur for 120 s, followed by injection of RB for
60 s. Next, either RB alone (channel 1) or RB with 100 nMmAb
(channel 2) was injected for 120 s, followed by a return to RB
alone. In channel 3, 51-Fc was pre-mixed with 100 nM mAb
before injection onto the chip. The three-stage injection
described above (integrin-buffer-buffer or integrin-buffer-
mAb) was accomplished using the “Coinject Analyte” com-
mand. Injection quality was set at “maximum.” The integrin
concentration used was 6 nM. In experiments with 3S3 and 6S6,
the concentration of mAb was 200 nM and integrin concentra-
tion was 3 nM. The concentrations ofmAb used gave amaximal
effect in the assays.
All binding sensorgrams were collected, processed, and ana-
lyzed using the integrated ProteOn Manager software (Bio-
Rad). Short black segments on some sensorgrams represent
artifact (spike) removal from the data. Dissociation rates (koff)
were calculated using off-rate analysis (ProteOnManager soft-
ware) using Equation 1,
A  A0  expkoff t t0 (Eq. 1)
where A0 binding at time t0. All results shown are represen-
tative of at least three separate experiments.
Epitope Mapping of Lia1/2—Mapping of the Lia1/2 epitope
was performed essentially as described previously for other
function-perturbing anti-1 mAbs (32, 41). The M287V
human-to-mouse mutation was made in human 1-GFP (65)
using the QuickChange XL mutagenesis kit (Agilent Technol-
ogies) according to the manufacturer’s instructions. CHO-K1
cells were transiently transfected with either wild-type or
mutant integrin by nucleofection (Lonza), and the binding of
Lia1/2 was detected by flow cytometry using an LSR Fortessa
cytometer (BD Biosciences) with AlexaFluor 647 anti-mouse
IgG (Stratech) as secondary antibody after gating the cells for
those expressing GFP. These assays were repeated twice, with
the same overall results.
Effect of 50K and cRGD on mAb Binding—Purified 51-Fc
was diluted 1:1000 with Dulbecco’s PBS (final concentration
2 g/ml), and 50-l aliquots were added to the wells of a
96-well ELISA plate (Costar 1⁄2-volume). Plates were incubated
overnight at room temperature, and wells were blocked for 1–3
hwith 200l of 5% (w/v) BSA, 150mMNaCl, 0.05% (w/v)NaN3,
25 mM Tris-HCl, pH 7.4. Wells were then washed three times
with 200 l of 150 mMNaCl, 25 mM Tris-HCl, pH 7.4, contain-
ing 1 mg/ml BSA (buffer A) with 1 mM MnCl2. mAbs (0.1
g/ml) in buffer A with 1mMMnCl2 were added to the wells in
the presence of varying concentrations of cRGD or 50K. The
plate was then incubated at room temperature for 2 h.
Unbound antibody was aspirated, and the wells were washed
three times with buffer A. Bound antibody was quantified by
FIGURE 11. A, effect of function-blocking mAbs on HT-1080 cells pre-spread
on 50K. Cells were allowed to spread on 50K for 1 h and then exposed to the
indicated anti-5 (JBS5, 16, P1D6, or SNAKA52) or anti-1 (13, 4B4, AIIB2, or
Lia1/2) mAbs for 1 h. The percentage of spread cells was then quantitated.
The non-function-blocking anti-5 mAb 11 and anti-1 mAb K20 were used
as controls. B, effect of the same mAbs in an assay in which the mAbs were
added to the cells before spreading on 50K. Similar results were obtained in
three separate experiments.
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addition of 1:1000 dilution of goat anti-mouse or anti-rat per-
oxidase conjugate (Jackson ImmunoResearch) in buffer A with
1 mM MnCl2 for 30 min at room temperature. Wells were then
washed four timeswith buffer A, and color was developed using
2,2
-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) sub-
strate. Measurements obtained were the means  S.D. of four
replicate wells. Experiments examining the effect of varying
concentrations of cRGDon the binding of Lia1/2 at 0.05 and 0.5
g/ml were performed in the same manner.
Competitive ELISA—ELISA plates were coated with 51-
Fc, blocked, andwashed as described above. Biotinylated Lia1/2
(0.1 g/ml) in buffer A was added to the wells in the absence or
presence of a large excess of unlabeled competitor mAbs (10 or
30 g/ml for 3S3 and 6S6). The plate was then incubated at
room temperature for 2 h. Unbound antibodies were aspirated,
and the wells were washed three times with buffer A. Bound
biotinylated antibody was quantified by the addition of 1:500
dilution of ExtrAvidin peroxidase conjugate in buffer A for 30
min at room temperature. Wells were then washed four times
with buffer A, and color was developed using 2,2
-azino-bis(3-
ethylbenzothiazoline-6-sulfonic acid) substrate. Measure-
ments obtained were the means  S.D. of four replicate wells.
In all the plate assays described above, the amount of nonspe-
cific bindingwasmeasured by determining the level of antibody
binding to wells coated with BSA alone; these values were sub-
tracted from the corresponding values for receptor-coated
wells. Each experiment shown is representative of at least three
separate experiments.
Cell Aggregation Assays—Jurkat cells were maintained in
complete RPMI 1640medium (supplemented with 2mM gluta-
mine and 10% fetal bovine serum). Aggregation assays were
performed essentially as described by Lee et al. (42). Cells (5
105/ml) were incubated in medium alone or in medium with
mAbs (1 g/ml) in a 96-well plate (Costar). After a 2-h incuba-
tion, cells were photographed with an inverted light micro-
scope (Leica DM IL) equipped with a Leica DFC295 video cam-
era. Themean aggregate size of three independent fields of view
was quantified in ImageJ (66) by converting each image to
binary and using the “analyze particles” function tomeasure the
size of each aggregate in the field. Results are presented as
mean S.D. of mean aggregate size over the three fields.
For inhibition experiments, cells were pre-incubated with 10
M C6-ceramide or an equivalent volume of solvent (DMSO)
only for 1 h at 37 °C before addition of themAbs (42). All results
shown are representative of three separate experiments.
Molecular Modeling—To model the position of 3FN9,10
bound to the headpiece of51, the superposition of the crystal
structures of the RGD-bound 51 (Protein Data Bank code
4WK4, with RGD peptide removed) (18) and the V3–3FN10
complex (Protein Data Bank code 4MMX) (49) was generated
using PyMOL (version 1.7.2.3; Schro¨dinger, LLC). The NMR
structure of 3FN9,10 (Protein Data Bank code 2MFN; model
10) (50) was docked onto 51 by alignment with 3FN10 of the
V3–3FN10 complex. The obminimize function in Open
Babel (version 2.3.1) (67) was used to confirm geometry opti-
mization and energy minimization for the aligned molecules.
Images were rendered in PyMOL and assembled using Illustra-
tor (version CS6; Adobe). A video representation of the model
was generated in PyMOL.
Cell Spreading Assays—HT-1080 fibrosarcoma cells were
maintained in complete Dulbecco’s modified Eagle’s medium
supplemented with 2 mM glutamine and 10% fetal bovine
serum.Wells of a 96-well plate (Costar)were coatedwith 50K (2
g/ml in Dulbecco’s PBS) for 60min at room temperature, and
then sites on the plastic for nonspecific cell adhesion were
blocked for 30 min at room temperature with 100 l of 10
mg/ml heat-denatured BSA. HT-1080 cells were detached with
0.05% trypsin, 0.02% EDTA, resuspended to 5  105/ml in
serum-free Dulbecco’s minimal essential medium with 25 mM
HEPES, and allowed to recover for 10 min at 37 °C. Cells were
then added to the wells and allowed to spread for 60 min in a
humidified atmosphere of 5% CO2 at 37 °C. mAbs were then
added towells to a final concentration of 10g/ml, and the cells
were incubated for a further 60 min. The cells were then fixed
with 3% glutaraldehyde, and the degree of spreading was quan-
tified using phase-contrast microscopy. Each data point
(mean S.D.) was obtained by counting three sets of 100 cells/
well from a number of randomly selected fields. In a parallel
assay, mAbs were added to the cells at the same time as plating
on 50K. No cell spreading was observed on wells coated only
with heat-denatured BSA.
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